Susceptibility to amphotericin B of Candida spp. strains isolated in Ceará, Northeastern Brazil

Silva, Cecília Rocha da; Magalhães, Hemerson Iury Ferreira; Moraes, Manoel Odoríco de; Júnior, Hélio Vitoriano Nobre

doi:10.1590/0037-8682-1060-2013

Cited by 4 publications

(3 citation statements)

References 13 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three papers were placed on the agar. The minimum inhibitory concentration (MIC) of AMB for C. albicans is 0.2-1.0 µg/mL, 16 and thus 2.5, 5, 10, 20, and 40 µL of AMB-NPs, at 10.6 µg/mL (equivalent to 1.0 µg/mL AMB), and free AMB, at 1.0 µg/mL, were separately dropped onto the filter paper, followed by incubation for 4 hours at room temperature. Then, the plates were incubated at 28°C for 9 days, and digital photographs were taken.…”

Section: Antifungal Activity In Vitromentioning

confidence: 99%

Enhanced antifungal effects of amphotericin B-TPGS-b-(PCL-ran-PGA) nanoparticles in vitro and in vivo

Tang¹,

Zhu²,

Sun³

et al. 2014

IJN

View full text Add to dashboard Cite

Background Amphotericin B (AMB) is a polyene antibiotic with broad spectrum antifungal activity, but its clinical toxicities and poor solubility limit the wide application of AMB in clinical practice. Recently, new drug-loaded nanoparticles (NPs) – diblock copolymer D-α-tocopheryl polyethylene glycol 1000 succinate-b-poly(ε-caprolactone-ran-glycolide) (PLGA-TPGS) – have received special attention for their reduced toxicity, and increased effectiveness of drug has also been reported. This study aimed to develop AMB-loaded PLGA-TPGS nanoparticles (AMB-NPs) and evaluate their antifungal effects in vitro and in vivo. Methods AMB-NPs were prepared with a modified nanoprecipitation method and then characterized in terms of physical characteristics, in vitro drug release, stability, drug-encapsulation efficiency, and toxicity. Finally, the antifungal activity of AMB-NPs was investigated in vitro and in vivo. Results AMB-NPs were stable and spherical, with an average size of around 110 nm; the entrapment efficacy was closed to 85%, and their release exhibited a typically biphasic pattern. The actual minimum inhibitory concentration of AMB-NPs against Candida albicans was significantly lower than that of free AMB, and AMB-NPs were less toxic on blood cells. In vivo experiments indicated that AMB-NPs achieved significantly better and prolonged antifungal effects when compared with free AMB. Conclusion The AMB-PLGA-TPGS NP system significantly improves the AMB bioavailability by improving its antifungal activities and reducing its toxicity, and thus, these NPs may become a good drug carrier for antifungal treatment.

show abstract

Section: Antifungal Activity In Vitromentioning

confidence: 99%

Enhanced antifungal effects of amphotericin B-TPGS-b-(PCL-ran-PGA) nanoparticles in vitro and in vivo

Tang¹,

Zhu²,

Sun³

et al. 2014

IJN

View full text Add to dashboard Cite

show abstract

“…The present study also agrees with that of [22] who reported that Amphotericin B was the most effective drug to which all isolates of Candida species except C. krusei were 100% sensitive. Other reports of very high susceptibility of Candida species to Amphotericin B have been documented [17,31,24]. Owing to its high toxicity (especially nephrotoxicity) and low bioavailability (when administered orally), Amphotericin B is not regularly prescribed or used extensively.…”

Section: In Vitro Susceptibility Profile Of the Candida Species To Nymentioning

confidence: 99%

Antifungal Resistance Pattern of Candida Species Isolated from High Vaginal Swabs of Women Attending a Hospital in Enugu State, Nigeria

Ezeadila

Okoli

Oyeka

2020

JAMB

View full text Add to dashboard Cite

There is an increase in non-albicans Candida (NAC) vulvovaginal candidiasis which is attributed to overuse of antifungal therapy and this has led to antifungal resistance. This study was aimed at determining the antifungal resistance pattern of some clinical isolates of Candida species. Eighty-eight (88) isolates were used which included Candida tropicalis (34), Candida Parapsilosis (21), Candida albicans (20), Candida krusei (7) and Candida glabrata (6). The drugs used were Fluconazole (25µg), Ketoconazole (10µg), Voriconazole (1µg), Nystatin (100Units), Amphotericin B (20µg), Flucytosine (1µg), Clotrimazole (10µg) and Itraconazole (50µg). The susceptibility testing was carried out using the M44-A standard method for yeast disk diffusion testing. Results showed that the percentages of Candida species resistant to Fluconazole, Ketoconazole, Voriconazole, Amphotericin B, Flucytosine, Clotrimazole and Itraconazole and Nystatin were 52.3%, 61.9%, 35.2%, 19.3%, 86.4%, 34.1%, 45.5% and 44.3%, with inhibition zone diameters ≤14mm, ≤20mm, ≤13mm, <10mm, ≤11mm, ≤11mm, ≤13mm and no inhibition zone diameter respectively. Candida krusei was the most resistant species with 100% resistance to each of Fluconazole, Ketoconazole and Flucytosine. Candida tropicalis was the species with the highest susceptibility (79.4%) to Amphotericin B followed by Candida parapsilosis with inhibition zone diameters ≥15mm. While Candida glabrata showed 100% resistance to each of Flucytosine and Itraconazole, Candida albicans showed 100% resistance to Flucytosine only. Candida glabrata was the only Candida species with 0% resistance to Amphotericin B. The drug to which most of the Candida species were susceptible was Amphotericin B followed by Voriconazole while Flucytosine was the drug with the highest resistance followed by Ketoconazole and Fluconazole. The highest number of susceptible-dose dependent Candida isolates was observed with Ketoconazole (25%), followed by Clotrimazole and Itraconazole, each recording 23.9%. Based on the findings of the present study, Voriconazole is recommended for vaginal candidiasis especially in the study area and also especially for infections caused by Fluconazole-resistant Candida species. This suggests that routine sensitivity testing is pertinent to guiding the choice of antifungal therapy. Thus, indiscriminate use of antifungal drugs should be avoided to reduce the development and spread of resistance.

show abstract

“…showed cross resistance between Azoles (20) and Terbinafine too (21). The total percentage of cross resistance was 62% (13/21) and the maximum was seen in C. albicans, C. glabrata, C.krusei and C. guilliermondii (Table 3).…”

Section: Cross Resistance Pattern Amongmentioning

confidence: 99%

Untitled

2014

IJPSR

View full text Add to dashboard Cite

Background: Drug resistance among Candida species constitutes the most significant problem in the treatment of Candidiasis.Systematic studies on antifungal drug susceptibility which may be useful in deciding clinical strategies are not routinely done in India and other developing countries. Objective: Aim of this study was testing sensitivity of clinical isolates of Candida albicans and non albicans to frequently prescribe antifungal drugs, fluconazole, ketoconazole, Itraconazole, Amphotericin B and Terbinafine. Material and methods: 25 strains of C. albicans and non albicans were tested in vitro for susceptibility to five antifungal agents, by using standard broth macro dilution method (CLSI M 27-A). Results: The present study revealed the percentage and extent of emerging drug resistance and cross resistance among Central Indian clinical isolates of C. albicans and non albicans against azoles and allylamine. In the present study, the total percentage of resistance was found to be 84% (21/25). The drug for which maximum resistance were found was Ketoconazole (64%) followed by Itraconazole (44%) Terbinafine (24%) and lastly Fluconazole (20%). The total percentage of cross resistance was 62% (13/21) and the maximum seen in C. albicans followed by C. glabrata, C. krusei and C. guilliermondi. No resistance was found for polyene drug Amphotericin B. Conclusion: This short study from India has exhibited the increasing frequency of resistance and Cross resistance of C.andida species against azoles and allylamine. We suggest a comprehensive study to determine the extent and degree of antifungal drug resistance among Candida species in India. INTRODUCTION: The genus Candida includes several species implicated in human pathology. Candida albicans is by far the most common species causing infections in humans. The emergence of non-albicans Candida species as a significant pathogens has however been well recognized during the past decade. 1

show abstract

Susceptibility to amphotericin B of Candida spp. strains isolated in Ceará, Northeastern Brazil

Cited by 4 publications

References 13 publications

Enhanced antifungal effects of amphotericin B-TPGS-b-(PCL-ran-PGA) nanoparticles in vitro and in vivo

Enhanced antifungal effects of amphotericin B-TPGS-b-(PCL-ran-PGA) nanoparticles in vitro and in vivo

Antifungal Resistance Pattern of Candida Species Isolated from High Vaginal Swabs of Women Attending a Hospital in Enugu State, Nigeria

Untitled

Contact Info

Product

Resources

About